Introduction

During the 2018 annual meeting of the Vit-Buckle Society, a panel of experts gathered for a roundtable discussion to review the effects of current treatment paradigms on real-world outcomes for patients with diabetic macular edema. The panelists also discussed how to customize and optimize treatment strategies for individualized patient care, taking into consideration the real-life burden of treatment on today’s patients and the damaging impact of persistent or recurring edema.

I would like to thank the faculty members for their participation, as well as Alimera Sciences for supporting this OSLI Retina supplement. For more information on this topic, visit Healio.com/OSLIRetina.

Darius M. Moshfeghi, MD
Editor-in-Chief
OSLI Retina

MODERATOR

David A. Eichenbaum, MD,
is partner at Retina Vitreous Associates of Florida and affiliate assistant professor of ophthalmology at the Morsani College of Medicine at the University of South Florida in Tampa.

Dr. Eichenbaum is a paid consultant for Alimera Sciences, Genentech, Regeneron Pharmaceuticals, Allergan, and Notal Vision; is an investigator for Mylan, Genentech, Allergan, Clearside Biomedical, Alcon Laboratories, Alimera Sciences, and Ophthalmotech Corporation; has received honoraria from Genentech and Allergan; and is a stockholder in Clearside Biomedical, US Retina, Hemera Biosciences, and Boston Image Reading Center.

FACULTY

Carlos Buznego, MD,

is a founding partner and past president of the Center for Excellence in Eye Care in Miami, Florida.

Dr. Buznego reports no relevant financial disclosures.

Dilsher S. Dhoot, MD,
is in private practice with California Retina Consultants in Santa Barbara.

Dr. Dhoot is a paid consultant for Alimera Sciences, Allergan, Regeneron Pharmaceuticals, Notal Vision, Genentech, and Santen Pharmaceutical.

Veeral S. Sheth, MD, MBA, FACS,
is director of clinical research at University Retina and Macula Associates in Lemont, Illinois, and clinical assistant professor at the University of Illinois, Chicago.

Dr. Sheth is a paid consultant for Alimera Sciences and is on the Speaker Bureau for Alimera Sciences and Genentech.

Christina Y. Weng, MD, MBA,
is an assistant professor of ophthalmology and the fellowship program director of vitreoretinal diseases and surgery at the Baylor College of Medicine in Houston, Texas.

Dr. Weng is a paid consultant for Alimera Sciences and Allergan.

Charles C. Wykoff, MD, PhD, FACS,
is director of research for Retina Consultants of Houston, deputy chair of ophthalmology at Blanton Eye Institute, and associate professor of ophthalmology at Houston Methodist Hospital in Texas.

Dr. Wykoff is a paid consultant for Alimera Sciences, Allergan, Regeneron Pharmaceuticals, Genentech, Roche, and Bayer.

All faculty members have received a modest honorarium from SLACK Incorporated for their contributions to this supplement.

doi: 10.3928/23258160-20180523-01